干细胞之家 - 中国干细胞行业门户第一站
标题:
求助书籍
[打印本页]
作者:
wenwen629
时间:
2010-12-3 09:31
标题:
求助书籍
Dübel, Stefan (ed.)
* B5 l- }* l. a( h
Handbook of Therapeutic Antibodies
( J' ~6 L" s+ H
Technologies, Emerging Developments and Approved Therapeutics
; r! r y0 m! k4 u
' |' B# U! S# b0 q
1. Edition - July 2010
8 f2 a% B; ^% a; z
199.- Euro
3 P8 \# D( k; ~' a9 C# z3 a! @9 o
2010. XLVI, 1204 Pages, Softcover
( g# H, w3 `# I. c8 _4 G( S& O l
200 Fig. (100 Colored Fig.)
( O$ _$ z# _3 C5 Q0 G
- Handbook/Reference Book -
- a9 w& S2 P0 Y' J
ISBN-10: 3-527-32902-1
% z9 x# ]& h% Q
有目录也可，求书！
作者:
hdc2001
时间:
2012-2-29 21:45
我也想要。
作者:
hdc2001
时间:
2012-2-29 21:46
Section I: Technologies
$ {6 Z$ U5 Y7 A# |# r
Foreword
0 |" X0 @8 C+ p( r3 c
A Greeting from the Editor
8 p1 A( T( w: }) }
PART 0: INTRODUCTION
; `6 d% h7 R; p4 P8 ]( X6 Y
Therapeutic Antibodies - From Past to Future
% o1 @* {: P- v \: o' {+ p0 B
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
* Q' d$ I# B4 C5 |9 z1 ?
Selection strategies I: Monoclonal Antibodies
) j: r: g, J& D0 N/ V# ~: X
Selection strategies II: Antibody Phage Display
% h7 a) Z" |/ e7 z- B0 V
Selection strategies III: Transgenic Mice
4 d! \* m E+ o$ U+ I9 f. v( j& D
Bioinformatic Tools for Antibody Engineering
- u6 f$ ]; n' \
Molecular Engineering I: Humanization
l" O S" V0 A( E, G
Molecular Engineering II: Affinity Maturation
: T; f* U. _( P7 d( |+ s" N7 K
Molecular Engineering III: Fc Engineering
# C+ Z0 E' Q: M: S( I2 E
PART II: THE WAY INTO THE CLINIC
. g. R3 J) l4 K; n0 O) l& |
Production and Downstream Processing
4 y5 E0 [- @5 E
Pharmaceutical Formulation and Clinical Application
6 l$ ?% y% M) v7 X
Immunogenicity of Antibody Therapeutics
- m2 a3 |, }% B' O' n! }
Regulatory Considerations
: \2 h: r0 n, _1 R# Y( Y
Intellectual Property Issues
1 \% j+ P+ n- ^
( t* U. M4 W; v
Section II: Emerging Developments
9 G) T1 I, G) D
PART III: BEYOND IGG: MODIFIED ANTIBODIES
# K2 ~. Q% ?' t
Immunoscintigraphy and Radioimmunotherapy
- P& z* `, M" \1 ]) h# _9 x
Bispecific Antibodies
1 v2 D7 @1 x X+ B
Immunotoxins /
; x T1 i) {8 d2 {# c3 ~
Targeted RNases
1 }4 L& ~: B. u1 c
PART IV: EMERGING CONCEPTS
2 }( x; _6 }3 ^3 B
Automation of Selection and Engineering
$ V7 V; A4 O$ h9 j4 |# _& V7 }
Emerging Technologies for Antibody Selection
! e# Y& s6 \. u9 l" X
Emerging Alternative Production Systems
* H2 }* a4 E; V w3 I7 d
Non-Antibody Scaffolds
! W: F8 G5 U2 f4 a9 [, a
Emerging Therapeutic Concepts I: ADEPT
3 E& N! b& z$ U* P# M9 B3 d
Emerging Therapeutic Concepts II: Nanotechnology
9 U4 k3 q9 Q' B, P: I
Emerging Therapeutic Concepts III:Cell-bound antibodies
& A$ a, q5 P2 t5 a
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
* e& U" e; m: M3 x7 @ \# D( x( c
PART V: ONGOING CLINICAL STUDIES:
+ {! M1 q" i: L3 G) k- Z" e; _
Antibodies in Phase I/II/III: Cancer Therapy
* r' M5 p. h* B
Antibodies in Phase I/II/III: Targeting TNF
; \6 B9 F4 R8 S1 ]( P
" l2 S2 H+ Z+ M7 }
Section III: APPROVED THERAPEUTICS
' n+ L7 x% e! O5 v# {
Adalimumab (Humira)
1 D8 }7 O# q$ K" V
Alemtuzumab (Mabcampath)
2 n" w: A3 Z$ a; R: L, `5 c
Bevacizumab (Avastin)
5 f1 Q& ]/ t1 u* Y
Cetuximab (Erbitux)
- [' V2 I& G- l. G3 M
Efalizumab (Raptiva)
3 ~8 J: C: S/ Y6 F# A6 s
Fanolesomab/Technetium99m (Neutrospec)
1 D3 R2 ]. X" D p1 _9 S
Gemtuzumab Ozogamicin (Mylotarg)
8 L2 d$ \+ d$ j& q
Infliximab (Remicade)
q/ \8 F( u& c3 I5 A9 B8 w, h
Muromonab (Orthoclone)
, l* M7 ~7 b# R
Natalizumab (Tysabri)
8 H' L+ G+ V" d! T5 G$ l8 Z. Z/ h
Omalizumab (Xolair)
' Q1 A, w, t3 A8 X- _# D
Palivizumab (Synagis)
# W1 H2 h3 L) h2 ?/ N* g% m
Rituximab (Rituxan)
. k$ \; m& o- C
Trastuzumab (Herceptin)
8 b4 _) \) X$ J9 ^7 Q
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
- a, }( V. |" I9 O4 c# E9 \
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)
6 B6 ?. `- E: c$ l; D7 R7 B
作者:
wenwen629
时间:
2013-4-28 11:13
回复
hdc2001
的帖子
$ _0 ?, M: M# W% t4 p5 U
9 A, L5 G' s; ]# B% I
谢谢。
欢迎光临 干细胞之家 - 中国干细胞行业门户第一站 (http://www.stemcell8.cn/)
Powered by Discuz! X1.5